title: Cerivastatin-induced rhabdomyolysis: 11 case reports.
abstract: 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are a frequently prescribed class of drugs that are generally well tolerated by most patients. A rare, yet serious side effect associated with these drugs is rhabdomyolysis. Although all HMG-CoA reductase inhibitors can cause this adverse effect, prevalence may differ among specific agents. Over a 16-month period, in three hospitals, 11 patients experienced cerivastatin-induced rhabdomyolysis, but no cases of rhabdomyolysis associated with any other HMG-CoA reductase inhibitors were reported.
authors.affiliation: University of the Pacific Thomas J. Long School of Pharmacy and Health Sciences, Stockton, California, USA. sravnan@chw.edu
authors.forename: Susan L
authors.initials: SL
authors.lastname: Ravnan
authors.forename: Christy
authors.initials: C
authors.lastname: Locke
authors.forename: William P
authors.initials: WP
authors.lastname: Yee
authors.forename: Kelli
authors.initials: K
authors.lastname: Haase
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000009:adverse effects*; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000378:metabolism
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; C086276:cerivastatin